Immutep Limited Updates On LAG-3 Therapeutics.pdf

IMMP), a global leader in LAG-3 therapeutics, presented an update on its business. Immutep is developing novel immunotherapies for cancer and autoimmune diseases through four product candidates targeting the promising immune checkpoint, LAG-3.

Clinical Potential:

Immutep's product candidates show clinical potential in various indications with high unmet needs, including:

Oncology (melanoma, HNSCC, MBC)
Autoimmune diseases (psoriatic arthritis, RA)

Global Leadership in LAG-3:

The company has a strong global leadership position in LAG-3 therapeutics, as evidenced by:

14 total clinical trials involving LAG-3 antagonists and agonists across multiple partners.
Immutep's own programs include eftilagimod alpha (IMP761), relatlimab (BMS), ieramilimab, and favezelimab (Merck & Co.).

Collaboration Deals:

Immutep has executed collaboration deals with industry leaders like Bristol-Myers Squibb (BMS), Merck & Co., and others, demonstrating the potential of its technology.

Corporate Strategy:

The company aims to develop product candidates for sale, licensing, or partnership with large pharmaceutical companies at key value inflection points.

LAG-3 Landscape:

Immutep's programs stand out in a competitive landscape due to their advanced stages and strong partner support.

Key Takeaways:

Immutep is well-positioned in the rapidly growing LAG-3 therapeutic market with diverse product candidates.
Robust clinical trial pipeline suggests significant potential for its products in treating various diseases.
* Strategic partnerships enhance Immutep's ability to bring these innovative therapies to patients.